



COPY OF PAPERS  
ORIGINALLY FILED

DOCKET NO. 17243CIP3(AP)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Chow et al.  
Serial No.: 09/815,362; Conf. No. 4078  
Filed: March 21, 2001  
For: COMPOUNDS AND METHOD OF  
)  
) TREATMENT HAVING AGONIST-LIKE ACTIVITY SELECTIVE  
) AT ALPHA 2B OR 2B/2C ADRENERGIC RECEPTORS  
) Group Art Unit: 1626  
)

Examiner: Floyd D. Higel

I hereby certify that this correspondence is being deposited with the United States Postal Service in first class mail in an envelope addressed to: Assistant Commissioner for Patents, Box Inventorship Change, Washington, D.C. 20231 on:

2/28/2002  
(Date of Deposit)

BONNIE FERLUSON  
Printed Name of Person Making Deposit

Bonnie Ferguson  
Signature

2/28/2002  
Date of Signature

RECEIVED  
AUG 22 2002  
TECH CENTER 1600/2900

RECEIVED

AUG 06 2002

TECH CENTER 1600/2900

STATEMENT OF DARIO G. GOMEZ

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

I, Dario G. Gomez, am an inventor of the subject matter claimed in the above-referenced patent application.

At the time the invention was made I was employed by Allergan, Inc., the parent company of the assignee Allergan Sales, Inc. I was unaware that this continuing application was filed until after the filing date, and therefore had no opportunity to advise Allergan that the inventor information, including the list of inventors, was incomplete. Thus, the incorrect naming of the inventive entity in this patent application was made without deceptive intent on my part; moreover, it is my understanding that such incorrect indication of inventors was an inadvertent error made when the patent application was filed.


Respectfully submitted,

Dated: 02/19/02

By: [Signature]  
Dario G. Gomez



COPY OF PAPERS  
ORIGINALLY FILED



DOCKET NO. 17243CIP5(A)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Chow et al.  
Serial No.: 09/815,362; Conf. No. 4078  
Filed: March 21, 2001  
For: COMPOUNDS AND METHOD OF  
TREATMENT HAVING AGONIST-LIKE ACTIVITY SELECTIVE  
AT ALPHA 2B OR 2B/2C ADRENERGIC RECEPTORS  
Group Art Unit: 1626  
Examiner: Floyd D. Higel  
Art Unit: )1626

I hereby certify that this correspondence is being  
deposited with the United States Postal Service as first  
class mail in an envelope addressed to: Box P01101 to  
Correct Inventorship, Assistant Commissioner for  
Patents, Box Inventorship Correction, Washington,  
D.C. 20231

2/28/2002  
(Date of Deposit)

BONNIE FERLUSON  
Printed Name of Person Making Deposit

Bonnie Ferguson  
Signature

2/28/2002  
Date of Signature

CONSENT OF ASSIGNEE TO CORRECTION OF INVENTORSHIP

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

As owner of the entire right, title, and interest in the above identified patent application, ALLERGAN hereby consents to the correction of inventorship to add Dario G. Gomez as an inventor in the above-referenced patent application. ALLERGAN'S right to take action pursuant to 37 CFR 3.73 is established in an Assignment from the inventors to ALLERGAN recorded in the Patent and Trademark Office on August 16, 1996 at Reel 8135, Frame 0552.

I, the undersigned, declare that I am authorized to make this appointment on behalf of Allergan Sales, Inc.

Respectfully submitted,

Martin A. Voet  
Assistant Secretary  
Allergan Sales, Inc.  
2525 Dupont Drive  
Irvine CA 92612